Summaries are drawn from public sources and link to them. HSH does not give a risk rating: read the summary and sources and reach your own view. Unproven allegations are labelled as such. Suppliers can submit a response, which is shown alongside.
Latest full-year results from official filings.
Listed (HOLX); FY2025 full-year figures not yet captured, so not assessed.
Agreed in Oct 2025 to be acquired by Blackstone and TPG funds (up to $79 a share).
Credible news about incidents, disputes, legal action or restructuring in the last 24 months.
Apr 2026: Blackstone and TPG completed their take-private of Hologic for up to $79 per share; Joe Almeida replaced Stephen MacMillan as CEO. Jul 2026: a class action filed in Massachusetts alleges personal data was exposed in a cyberattack on Hologic.
Data breaches, cyber incidents, regulator action and assurance status.
Jul 2026: a class action lawsuit alleges sensitive personal data held by Hologic was exposed in a ransomware attack; HSH did not find a company confirmation of the incident in its search. NHS DSPT status not yet checked.
Recalls, safety notices, regulator action and clinical safety concerns.
Jul 2026: FDA updated the BioZorb breast marker recall, citing 252 reported injuries and no deaths; Hologic stopped shipping the markers in 2024. Dec 2024: an FDA warning letter cited design control, CAPA and adverse-event reporting failures for BioZorb.
Contract delivery, go-lives, terminations and disputes.
No notable troubled implementations, terminations, customer disputes or significant new NHS contracts involving Hologic found in HSH's search of the last 24 months.